Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
5
VanEck Oil Services ETF
OIH
US Stock MarketDetailed Quotes
Bicycle Therapeutics (BCYC)
- 4.090
- -0.080-1.92%
Trading Jun 10 12:00 ET
285.53MMarket Cap-1.30P/E (TTM)
4.240High4.065Low117.75KVolume4.130Open4.170Prev Close488.34KTurnover0.31%Turnover RatioLossP/E (Static)69.81MShares9.18352wk High0.52P/B157.18MFloat Cap3.99052wk Low--Dividend TTM38.43MShs Float62.075Historical High--Div Yield TTM4.20%Range %3.990Historical Low4.147Avg Price1Lot Size
Bicycle Therapeutics (BCYC) News
Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)
Bicycle Therapeutics Reports Positive Duravelo-2 Phase 2 Data
Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Improved Safety Profile In Metastatic Urothelial Cancer Phase 2 Study
Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $4.45
Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $5
Truist Financial Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Cuts Target Price to $7
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $7 to $15
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Irhythm Technologies (IRTC) and Bicycle Therapeutics (BCYC)
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Option Care Health (OPCH)
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
Bicycle Therapeutics GAAP EPS of -$0.87 Misses by $0.20, Revenue of $0.89M Misses by $6.61M
Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate
Bicycle Therapeutics | 8-K: Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics | 10-Q: Q1 2026 Earnings Report
Express News | Bicycle Therapeutics Q1 Net Income USD -60.825 Million
Express News | Bicycle Therapeutics Q1 Pretax Profit USD -60.653 Million
Express News | Bicycle Therapeutics Q1 Operating Incom USD -65.482 Million
Express News | Bicycle Therapeutics Q1 Operating Expenses USD 66.369 Million
Press Release: Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Tensions in the Middle East are escalating: Iran shot down a U.S. Apache helicopter, prompting retaliatory U.S. airstrikes on multiple locat
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm